Ranolazine dihydrochloride(Synonyms: 盐酸雷诺嗪; CVT 303 dihydrochloride; RS 43285)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ranolazine dihydrochloride (Synonyms: 盐酸雷诺嗪; CVT 303 dihydrochloride; RS 43285) 纯度: 99.79%

Ranolazine dihydrochloride (CVT 303 dihydrochloride) 是一种抗心绞痛和抗缺血剂，可通过抑制内向钠电流的后期作用 (对 INa 和 IKr 的 IC50 值分别为 6 μM 和 12 μM) 来发挥功效，而不会影响心率或血压。Ranolazine dihydrochloride 还是脂肪酸氧化的部分抑制剂。

Ranolazine dihydrochloride(Synonyms: 盐酸雷诺嗪; CVT 303 dihydrochloride; RS 43285)

Ranolazine dihydrochloride Chemical Structure

CAS No. : 95635-56-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥737 In-stock
100 mg ￥670 In-stock
200 mg ￥1100 In-stock
500 mg ￥1600 In-stock
1 g ￥2000 In-stock
5 g ￥6000 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Ranolazine dihydrochloride 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Membrane Transporter/Ion Channel Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Drug Repurposing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Neuroprotective Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

IC50 & Target

IC50: 6 μM (INa), 12 μM (IKr)[1]
体内研究
(In Vivo)

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (240-350 g)[3]
Dosage: Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h)
Administration: Bolus injection; for 145 minutes
Result: Significantly reduced infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

Clinical Trial

分子量

500.46

Formula

C24H35Cl2N3O4
CAS 号

95635-56-6
中文名称

盐酸雷诺嗪
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : ≥ 50 mg/mL (99.91 mM)

H2O : ≥ 50 mg/mL (99.91 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9982 mL 9.9908 mL 19.9816 mL
5 mM 0.3996 mL 1.9982 mL 3.9963 mL
10 mM 0.1998 mL 0.9991 mL 1.9982 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： PBS

    Solubility: 13000 mg/mL (25976.10 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73.

    [2]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.

    [3]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务